Dr. Thomas Abshire, MD

Pediatric Hematology-Oncology Milwaukee, WI Male
NPI: 1730249681
Total Payments
$188,770
2024 Payments
$20,612
Companies
8
Transactions
76

Payment Breakdown by Category

Research$84,354 (44.7%)
Consulting$64,329 (34.1%)
Travel$21,878 (11.6%)
Other$17,150 (9.1%)
Food & Beverage$1,060 (0.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $84,354 25 44.7%
Consulting Fee $64,329 16 34.1%
Travel and Lodging $21,878 19 11.6%
Honoraria $12,200 2 6.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,950 2 2.6%
Food and Beverage $1,060 12 0.6%

Payments by Type

General
$104,417
51 transactions
Research
$84,354
25 transactions

Top Paying Companies

Company Total Records Latest Year
Novo Nordisk AS $113,344 38 $0 (2024)
Shire North American Group Inc $26,224 11 $0 (2019)
Novo Nordisk Inc $21,817 10 $0 (2019)
CSL Behring $13,841 10 $0 (2018)
Takeda Pharmaceuticals U.S.A., Inc. $10,975 3 $0 (2021)
Blueprint Medicines Corporation $2,464 1 $0 (2024)
Kedrion Biopharma Inc. $72.81 1 $0 (2017)
Agios Pharmaceuticals, Inc. $31.80 2 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $20,612 5 Novo Nordisk AS ($18,148)
2023 $17,404 4 Novo Nordisk AS ($17,404)
2022 $31,793 9 Novo Nordisk AS ($31,793)
2021 $18,265 7 Takeda Pharmaceuticals U.S.A., Inc. ($10,975)
2020 $9,720 4 Novo Nordisk AS ($9,720)
2019 $26,314 14 Novo Nordisk Inc ($21,817)
2018 $41,617 23 Shire North American Group Inc ($21,728)
2017 $23,047 10 Novo Nordisk AS ($17,236)

All Payment Transactions

76 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
09/19/2024 Blueprint Medicines Corporation — Consulting Fee Cash or cash equivalent $2,464.00 General
09/01/2024 Novo Nordisk AS Alhemo (Drug) — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4307 • Category: Hemophilia
05/01/2024 Novo Nordisk AS Alhemo (Drug) — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4307 • Category: Hemophilia
02/28/2024 Novo Nordisk AS Alhemo (Drug) — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4307 • Category: Hemophilia
01/01/2024 Novo Nordisk AS Alhemo (Drug) — Cash or cash equivalent $3,867.50 Research
Study: NN7415-4307 • Category: Hemophilia
09/26/2023 Novo Nordisk AS — — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4311
04/01/2023 Novo Nordisk AS — — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4311
01/01/2023 Novo Nordisk AS — — Cash or cash equivalent $4,760.00 Research
Study: NN7415-4311
01/01/2023 Novo Nordisk AS — — Cash or cash equivalent $3,123.75 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — In-kind items and services $10,926.30 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — Cash or cash equivalent $8,505.00 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — In-kind items and services $285.43 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — In-kind items and services $100.48 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — In-kind items and services $71.98 Research
Study: NN7415-4311
09/01/2022 Novo Nordisk AS — — Cash or cash equivalent $23.38 Research
Study: NN7415-4311
06/01/2022 Novo Nordisk AS — — Cash or cash equivalent $3,240.00 Research
Study: NN7415-4311
02/01/2022 Novo Nordisk AS — — Cash or cash equivalent $4,320.00 Research
Study: NN7415-4311
01/01/2022 Novo Nordisk AS — — Cash or cash equivalent $4,320.00 Research
Study: NN7415-4311
10/01/2021 Novo Nordisk AS — — Cash or cash equivalent $1,620.00 Research
Study: NN7415-4311
07/15/2021 Takeda Pharmaceuticals U.S.A., Inc. VONVENDI (Biological) Consulting Fee Cash or cash equivalent $4,725.00 General
Category: HEMATOLOGY
07/15/2021 Takeda Pharmaceuticals U.S.A., Inc. VONVENDI (Biological) Consulting Fee Cash or cash equivalent $4,000.00 General
Category: HEMATOLOGY
06/07/2021 Takeda Pharmaceuticals U.S.A., Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,250.00 General
05/01/2021 Novo Nordisk AS — — Cash or cash equivalent $1,080.00 Research
Study: NN7415-4311
02/01/2021 Novo Nordisk AS — — Cash or cash equivalent $2,160.00 Research
Study: NN7415-4311
01/01/2021 Novo Nordisk AS — — Cash or cash equivalent $2,430.00 Research
Study: NN7415-4311
1234»

Research Studies & Clinical Trials

Study Name Company Amount Records
NN7415-4311 Novo Nordisk AS $56,486 17
NN7415-4307 Novo Nordisk AS $27,868 8

About Dr. Thomas Abshire, MD

Dr. Thomas Abshire, MD is a Pediatric Hematology-Oncology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730249681.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Abshire, MD has received a total of $188,770 in payments from pharmaceutical and medical device companies, with $20,612 received in 2024. These payments were reported across 76 transactions from 8 companies. The most common payment nature is "" ($84,354).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Location Milwaukee, WI
  • Active Since 12/11/2006
  • Last Updated 11/18/2011
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1730249681

Products in Payments

  • NovoSeven RT (Drug) $33,571
  • Alhemo (Drug) $18,148
  • VONVENDI (Biological) $8,725
  • Humate-P (Biological) $7,979
  • Multiple Products (Biological) $5,738
  • RHOGAM (Drug) $72.81
  • TIBSOVO (Drug) $31.80

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Milwaukee

Michael Burke, M.d, M.D

Pediatric Hematology-Oncology — Payments: $247,019

Pediatric Hematology-Oncology $247,019

Dr. Brian Branchford, M.d, M.D

Pediatric Hematology-Oncology — Payments: $93,841

Pediatric Hematology-Oncology $93,841

Dr. Robert Montgomery, Md, MD

Pediatric Hematology-Oncology — Payments: $35,013

Pediatric Hematology-Oncology $35,013

Ms. Veronica Flood, M.d, M.D

Pediatric Hematology-Oncology — Payments: $24,084

Pediatric Hematology-Oncology $24,084

Dr. Allison Remiker, M.d, M.D

Pediatric Hematology-Oncology — Payments: $12,000

Pediatric Hematology-Oncology $12,000

Dr. Julie-An Talano, Md, MD

Pediatric Hematology-Oncology — Payments: $10,736

Pediatric Hematology-Oncology $10,736